A carregar...
Patient cost-sharing during poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer
BACKGROUND: More patients with ovarian cancer are being treated with poly (ADP-ribose) polymerase (PARP) inhibitors as regulatory agencies have granted these drugs new approvals for a variety of treatment indications. However, PARP inhibitors are expensive. When given as a maintenance therapy, these...
Na minha lista:
| Publicado no: | Am J Obstet Gynecol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8254740/ https://ncbi.nlm.nih.gov/pubmed/33549538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajog.2021.01.029 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|